Johnson & Johnson Starts New Late Stage COVID-19 Vaccine Trial

The video discusses the testing of an A2 dose regimen for an experimental COVID-19 vaccine, focusing on the potential benefits of a second dose. The study aims to include up to 30,000 participants, while a previous A1 dose trial involved around 60,000 people. Additionally, Pfizer and BioNTech reported that their vaccine showed an efficacy rate of over 90%.

What are the potential benefits being studied with the second dose?

How many people participated in the A1 dose trial study last week?